Navigation Links
Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
Date:4/18/2008

r parts of the body, has an especially poor prognosis, with a five-year survival rate of 27 percent. Currently, there are two and a half million breast cancer survivors in the United States. According to the ACS, breast cancer death rates are going down; the decline may be the result of early detection and treatment.

About the Study

Prior to study initiation, the Norton-Simon mathematical model (Norton et al, AACR 2005) -- which explores how the growth characteristics of a cancer affect response to chemotherapy -- was applied to determine that the maximum impact of Xeloda treatment in breast cancer patients occurs after seven days. Based on this finding, the single-center, open-label phase I/II trial was designed to determine the maximum tolerated dose (MTD) of Xeloda administered orally for seven days, followed by a seven-day rest (7-on/7-off), in patients with advanced-stage breast cancer. MTD was defined as the highest dose for which the incidence of dose-limiting toxicity (DLT) is less than 33 percent. DLT was defined as grade 3/4 hematologic toxicity lasting greater than two weeks despite growth factor support, or any grade 3/4 nonhematologic toxicity.

The Phase I study dose escalation scheme was a standard "3+3" design, using flat dosing that begins at 1,500 mg twice daily and increases by 500 mg/dose level until the MTD is reached. All patients in a cohort were observed for 28 days before enrollment to the next level is permitted to monitor for delayed toxicity.

The study showed that the dose dense regimen was well-tolerated in patients with advanced breast cancer, allowing safe delivery of higher daily doses than routinely used in practice. Of the 21 patients recruited for the trial, 18 were treated with Xeloda and reached a maximum tolerated dose of 2,000 mg twice daily. There were no grade 4/5 toxicities and grade 3 toxicities (which included one dose-limiting incident of hand-foot syndrome at 2,000 mg twice daily and two at 2,0
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Aug. 28, 2014 Levi & Korsinsky announces ... the United States District Court for the District of ... who purchased Galectin Therapeutics Inc. ("Galectin" or the "Company") ... 28, 2014. For more information, click here: ... during the Class Period the Company violated federal securities ...
(Date:8/28/2014)... 28, 2014 Nonin Medical, Inc., the inventor ... medical monitoring, today announced that the Food and Drug ... finger pulse oximeter for use in the ... into a telemedicine hub or kiosk through a USB ... pediatric to adult patients. The Model 3231 received EU ...
(Date:8/28/2014)... Oregon , August 28, 2014 ... Research titled, "DNA diagnostics Market (products, applications, techniques, ... Trends, Opportunities, Growth and Forecast, 2013 - 2020," ... reach $19 billion by 2020 registering a CAGR ... to provide accurate diagnosis and cost effectiveness over ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3
... 2011 Quest Diagnostics Incorporated (NYSE: DGX ... and services, today announced the CE mark and European ... test on the 3M™ Integrated Cycler.  The new test, ... technique to eliminate nucleic-acid sample extraction, a time-consuming process ...
... N.J., Nov. 1, 2011 MedAvante, Inc., the world,s ... of treatments for central nervous system (CNS) disorders, announced ... 2011 Fifty Fastest Growing Companies. NJBIZ, New ... 50 Fastest Growing Companies in celebration of New Jersey,s ...
Cached Medicine Technology:Quest Diagnostics Announces Launch of Simplexa™ Direct Test for Influenza and Respiratory Viruses in Europe 2Quest Diagnostics Announces Launch of Simplexa™ Direct Test for Influenza and Respiratory Viruses in Europe 3MedAvante Is One of NJ's Fastest Growing Companies 2
(Date:8/28/2014)... about the chance of ,overdiagnosis, through the NHS breast ... according to research published in the British Journal ... survey of around 2,200 women, Cancer Research UK scientists ... cent felt they fully understood the information given about ... cancers that would never have gone on to cause ...
(Date:8/28/2014)... Millennium Treatment Group is excited ... month will be a celebration of the positive ... Along with other treatment facilities and mental health ... the word about this national observance. , National ... of treatment and recovery professionals, and has since ...
(Date:8/28/2014)... Millennium Treatment Group has noticed a ... workplace. A recent report from the National Council ... drug abuse is costing employers an estimated $81 billion ... to drugs affect their employers and the company they ... workplace, causing expensive problems for their employers, such as ...
(Date:8/28/2014)... HealthDay Reporter THURSDAY, Aug. 28, 2014 (HealthDay ... symptoms of multiple sclerosis (MS), a new study from Argentina ... D, smoking and Epstein Barr virus infection. Our study shows ... MS patients," said lead researcher Dr. Mauricio Farez, of the ... Multiple sclerosis is a disease of the nervous system that ...
(Date:8/28/2014)... 2014 Testimony began this week ... transvaginal mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ )involving a ... reports. Court documents pending in the U.S. District ... the case was filed on behalf of a ... allegedly due to vaginal mesh complications associated with ...
Breaking Medicine News(10 mins):Health News:Some women still don't underststand 'overdiagnosis' risk in breast screening 2Health News:Millennium Treatment Group Celebrates National Recovery Month 2Health News:Drug Use Causes Problems in the Workplace 2Health News:Could Too Much Salt Harm MS Patients? 2Health News:Could Too Much Salt Harm MS Patients? 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4
... [Brown University] More than 1.4 million Americans live ... million will need long-term care, whether in a nursing ... an at-home health service provider. , At this time ... on Aging has awarded Brown University a major grant ...
... 15 Danny Wright, Chief Executive Officer,of Alliance ... will be featured in an exclusive interview,with ... p.m. EST. The interview,will be posted on ... 16. The interview will cover topics including ...
... The Center for State and,Local Government Excellence ... Public Policy and Social Research (IPPSR) at Michigan ... the state,s unfunded retiree health,care liability. Michigan ... billion. To help policy leaders develop thoughtful solutions, ...
... NovaBay,Pharmaceuticals, Inc. (AMEX & TSX: NBY), a biopharmaceutical ... or prevention of a wide range of bacterial ... quarter ended September 30, 2007. Net loss ... $1.6 million, or,$0.24 per share, as compared to ...
... United States are estimated to already have bone diseases, ... low bone mass, putting them at increased risk for ... Wang, assistant professor of mechanical engineering at the University ... Two of Wang,s aunts have suffered from the insidious ...
... when a naturally occurring hormone in your body turns against ... melatonin is a popular supplement you take to ... his team of researchers may have some answers. ... biology and biochemistry at UH, describes his teams findings in ...
Cached Medicine News:Health News:Brown to create most comprehensive long-term care database 2Health News:Brown to create most comprehensive long-term care database 3Health News:WallSt.net Announces Upcoming Interview With CEO of Alliance HealthCard 2Health News:Center For Excellence to Fund Analysis of Michigan State Retiree Health Care Reforms 2Health News:NovaBay announces third quarter 2007 financial results 2Health News:NovaBay announces third quarter 2007 financial results 3Health News:NovaBay announces third quarter 2007 financial results 4Health News:NovaBay announces third quarter 2007 financial results 5Health News:NovaBay announces third quarter 2007 financial results 6Health News:NovaBay announces third quarter 2007 financial results 7Health News:Bad to the bone: UD research to shed light on osteoporosis 2Health News:Bad to the bone: UD research to shed light on osteoporosis 3Health News:The hormone of darkness: melatonin could hurt memory formation at night 2Health News:The hormone of darkness: melatonin could hurt memory formation at night 3
Intermittent catheter...
Intermittent catheter...
Intermittent catheter...
Diagnostic and laboratory test reference. Get help with test preparation, interpretation, follow-up, and reimbursement....
Medicine Products: